American National Bank & Trust Buys 1,183 Shares of Stryker Co. (NYSE:SYK)

American National Bank & Trust boosted its stake in Stryker Co. (NYSE:SYK) by 3.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,311 shares of the medical technology company’s stock after purchasing an additional 1,183 shares during the period. Stryker comprises 1.5% of American National Bank & Trust’s investment portfolio, making the stock its 19th largest position. American National Bank & Trust’s holdings in Stryker were worth $13,517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company’s stock valued at $11,773,213,000 after buying an additional 252,188 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Stryker by 0.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company’s stock valued at $4,000,056,000 after acquiring an additional 54,693 shares during the last quarter. FMR LLC boosted its holdings in shares of Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after purchasing an additional 727,850 shares during the period. Geode Capital Management LLC grew its stake in shares of Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company’s stock worth $2,539,033,000 after purchasing an additional 168,436 shares during the last quarter. Finally, Norges Bank purchased a new position in Stryker during the 4th quarter valued at about $1,710,744,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $382.86 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $146.13 billion, a P/E ratio of 49.34, a PEG ratio of 2.93 and a beta of 0.93. The stock’s 50 day moving average is $368.77 and its 200 day moving average is $376.14.

Stryker (NYSE:SYK) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.50 earnings per share. On average, equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker’s dividend payout ratio (DPR) is presently 45.41%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SYK shares. Sanford C. Bernstein set a $450.00 price objective on Stryker in a report on Monday, May 5th. Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. Evercore ISI cut their price target on shares of Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Barclays upped their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Roth Mkm lifted their target price on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.